Overview

Ivosidenib, also known by the research code AG-120 and marketed as Tibsovo, is an oral inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). It is indicated for certain adults with acute myeloid leukemia (AML) whose disease carries an IDH1 mutation, and is supplied as 250mg tablets in a 60-tablet pack. For distributors, ivosidenib sits in targeted oncology, where the commercial logic differs from conventional chemotherapy. The drug is tied to a defined molecular subgroup rather than prescribed broadly, and that single fact drives the supply chain — from the test that must precede the prescription to the documentation a distributor must hold.

IDH1 Testing as a Prerequisite

IDH1 mutations occur in a proportion of AML cases and are identified by molecular testing of bone marrow or blood samples. Because ivosidenib acts specifically on the mutant IDH1 enzyme, establishing the mutation's presence is the gate for appropriate use. This is the companion diagnostic model: test and therapy are linked, and the therapy is used in the population the test identifies.

The practical implication for B2B partners is that demand concentrates in centres with molecular diagnostic capability. That narrows the realistic buyer list — academic hospitals, comprehensive cancer centres and reference laboratories — so planning should be built around diagnostic infrastructure. Where a market lacks routine IDH1 testing capacity, adoption will be constrained regardless of availability.

Combination Therapy in AML

Targeted agents in AML are frequently used in combination with other antileukemic treatment rather than as monotherapy. Ivosidenib has been approved in combination with azacitidine, a hypomethylating agent used in myeloid malignancies, in adults with newly diagnosed IDH1-mutated AML. This reflects the standard pattern in AML, where agents with different mechanisms are combined.

The operational consequence matters. Combination regimens mean the ivosidenib order is often part of a wider oncology procurement basket, and a distributor able to supply companion products gains a structural advantage.

Cold Chain and Compliance Essentials

Although ivosidenib is an oral tablet rather than an injectable, it is still a prescription oncology product subject to strict handling requirements.

• Storage conditions. Follow the labeled storage instructions exactly, including any temperature range and moisture protection. Do not assume room-temperature storage without reading the label.
• Chain of custody. Maintain batch-level traceability from manufacturer release to the dispensing site. Oncology products are frequent targets of diversion.
• Authorisation. Confirm registration status in the market and that importation follows the correct route for a prescription oncology medicine.
• Expiry management. Use expiry-based rotation of this high-value stock and set firm terms on minimum remaining shelf life.

FAQ

Q: What does the 250mg x 60 tablets specification mean? A: It describes tablet strength and pack count as listed by the supplier: 250mg per tablet, 60 tablets per pack. Confirm the packaging format separately.

Q: Why is IDH1 mutation testing required before use? A: Ivosidenib inhibits the mutant IDH1 enzyme, so the mutation must be present for the drug's mechanism to apply. Testing identifies the patients the therapy targets.

Q: Is ivosidenib used alone or in combination? A: Both. It has been approved in combination with azacitidine for newly diagnosed IDH1-mutated AML, and is also used as a single agent. The regimen is set by the treating physician.

Q: Does the product name mean it is approved for all cancer stages? A: No. Its indications are specific to defined IDH1-mutated haematological conditions. "Stage" wording in some listings is marketing language, not a regulatory indication.